We are currently completing a Phase 1a/b clinical trial in patients with advanced or metastatic solid tumors. The Phase 1a portion investigated single agent activity with the Phase 1b in combination with nivolumab. Etigilimab is an anti-TIGIT therapeutic candidate designed to activate the immune system through multiple mechanisms and enable anti-tumor activity. TIGIT (T-cell immunoreceptor with Ig and ITIM domains) is an inhibitory receptor that is thought to prevent T-cells from attacking tumor cells, similar to the inhibitory protein PD-1.

PATIENT RESOURCES

Information on our anti-TIGIT clinical program is available here: MPH-313 ClinicalTrials.gov.

PUBLIC PRESENTATIONS OF DATA FROM OUR ANTI-TIGIT PROGRAM INCLUDE:

SCIENTIFIC PUBLICATIONS:

VIEW CLINICAL STUDIES

FOR PARTNERING